Lifeward, previously known as ReWalk Robotics, has received the CE mark approval for the sale of its ReWalk 7 Personal Exoskeleton in the European Union (EU).
ReWalk 7 is a seventh-generation exoskeleton that brings advanced features such as cloud connectivity, push-button controls, and adaptable walking speeds.
The company has been offering exoskeletons in Europe since 2010, and the latest version aims to provide greater mobility for individuals with spinal cord injuries (SCI).
Lifeward said that its ReWalk 7 Personal Exoskeleton enhances user interaction with stairs and curbs, providing a new level of independence for SCI patients.
The device now includes crutch control for easier use, a smartwatch for mode selection, and a mobile app for tracking.
The enhancements aim to boost user control in various environments. The system is tailored for each user, featuring adjustable settings for a natural walking experience.
Furthermore, Lifeward said that it has partnered with major German insurance carriers, including BARMER, to support the reimbursement and distribution of exoskeletons.
Lifeward CEO Mark Grant said: “The ReWalk 7 represents a major advancement in personal exoskeleton technology, designed to deliver superior control, engagement, and real-world mobility for individuals with SCI.
“Achieving CE mark approval is a pivotal regulatory milestone for Lifeward.
“With reimbursement already broadly established in Germany, this foundation positions us to drive meaningful near-term commercial adoption and revenue growth in Europe, while also providing a proven model we are beginning to replicate in other strategic markets, including the US.”
In April this year, Lifeward launched the ReWalk 7 Personal Exoskeleton in the US, for use by individuals with spinal cord injuries.
